News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

05.05.2025

Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex

05.05.2025

An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia by acinetobacter baumannii-calcoaceticus complex: A narrative review

05.05.2025

Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii-Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

05.05.2025

A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp

12.19.2024

Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data

12.11.2024

Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations

09.20.2024

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii

07.13.2024

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

06.24.2024

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

06.24.2024

Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii